SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Proton who wrote (13805)1/27/1998 2:12:00 PM
From: Andrew H  Read Replies (2) | Respond to of 32384
 
"The droloxifene news is a disappointment and creates a question about the drug's potential for the other two indications Pfizer is still
pursuing," said A.G. Edwards drug analyst Kenneth Nover."

I don't see why it would create questions about the osteo indication, but then PFE is not releasing much info. Your analysis that the merger action of the big boys might be hurting LGND and other biotechs makes sense.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News